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Introduction
DNA methylation is one of the most frequent chemical
modifications in the eukaryotic genome. It occurs in
the cells of fungi, plants, non-vertebrates and verte-
brates [1-4]. In mammals, this process is important for
the normal embryonic development, plays an impor-
tant role in regulation of gene expression, X chromo-
some inactivation, genomic imprinting, chromatin
modification and the silencing of endogenic genes.
Aberrations in the genome methylation pattern may
appear while the organism is ageing and in the early
stages of cancerogenesis, even 3 years before a clinical
diagnosis of cancer is possible [5-14].
The knowledge of a normal methylation process
and its aberrations appeared to be useful while search-
ing for new markers enabling an early detection of dif-
ferent types of human cancer. 
Biochemical process of DNA methylation 
DNA methylation involves a covalent addition of a
methyl group (-CH3) to the 5'carbon of the pyrimidine
ring of deoxycytidine (dC), which leads to the creation
of 5- deoxymethylcytidine (dmC). The reaction is
catalysed by DNA methyltransferases, whose sub-
strates are palindromic DNA sequences 5'-CG-3',
which are also referred to as CpG dinucleotides (Fig.
1) [10,11,15-17].
In genomes of most mammals (70% - 80%), CpG
sites with 5-methylcytidine are methylated on both
DNA strands, only a few CpG sequences have asym-
metrical methylation [10]. The frequency of 5-methyl-
cytidine in mammalian DNA is less than 1% of all
nucleotides, and the amount of all CpG dinucleotides
is four times smaller than predicted  [10,15]. This low
frequency of CpG dinucleotides in DNA particles may
be related to cytosine methylation. 5-methylcytosines
more often undergo spontaneous deamination compar-
ing to unmethylated cytosines.  This process leads to
the creation of thymine - a natural DNA component,
which is rarely recognized by intracellular repair sys-
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tems while the uracil, which appears after the deami-
nation of unmethylated cytosine, is easily removed
from DNA particles [10,15,18,19].
During evolution, the dinucleotides CpG have been
progressively eliminated from the genome of higher
eukaryotes and now they are present at only 5% to
10% of their predicted frequency [10,19].
Distribution of methylated and unmethylated
sequences in the genome 
Eukaryotic genomes contain methylated regions inter-
spersed with unmethylated domains. However, the
location of CpG dinucleotides and 5-methylocytosines
is not random [7,10,15].
Most of the genome shows significant methylation
and a low concentration of CpG dinucleotides (extra-
genic DNA). Such regions are typical of the condensed
chromatin that is formed during the late stage of DNA
replication as a result of reactions between histones
and conformational changes in nucleosomes. Hete-
rochromatin is inaccessible to transcription factors
[6,10,18,20].
The rest of the genome (l% - 2%) contains unmethy-
lated DNA. Pairs of CpG (length: 0.5 kb - 2kb) occur in
the area from 0.5 to 5 kb every 100 kb (located within
genes and gene related sequences) [10,15]. These
sequences are rich in CpG dinucleotides, which consti-
tute about 60% - 70%, and, for this reason, are called
CpG islands (C+G≥55%; the relation of CpG to predict-
ed CpG≥0.65). Chromatin containing CpG islands is
heavily acetylated (histone H3 lysine 9 -  H3Lys9 is often
acetylated), lacks histone H1 and includes a nucleosome-
free region.  This, so called, open chromatin configura-
tion may be a consequence of the interaction of tran-
scription factors with gene promoters  [15,18,20,21].
CpG islands occur mainly in the 5'end of genes, in
the region of promoter, and many of them contain tran-
scription factors binding sites. We differentiate two
types of promoters: rich and poor in CpG islands.
Approximately half of all human genes contain CpG
islands. These are housekeeping genes and some tis-
sue-specific genes (40% of tissue-specific genes)
[10,22].
Promoter region CpG islands are usually unmethy-
lated in all normal tissues, regardless of the transcrip-
tional activity of the gene. The genes situated on the
inactive X-chromosome and the genes undergoing
genomic imprinting are exceptions because one of the
parental alleles of these genes may be methylated. It
has also been found that CpG islands which are
unmethylated in young organisms can become methy-
lated as the organism ages (the, so-called, age-depend-
ent methylation), which may constitute a preliminary
stage of cancer-related cell transformation [7,9,10,
18,20,23].
DNA methyltransferases
The enzymes that transfer the methyl group to the
phenyl cytosine ring belong to the family of DNA
methyltransferases, which includes DNMTl,
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Fig. 1. DNA methylation reaction catalyzed by DNA Methyltransferase (DNMT) [56].
DNMT3A, DNMT3B and DNMT3L [11]. These pro-
teins have been found in the nucleolus and the nucleo-
plasm area. DNMT1 is responsible for maintaining the
methylation pattern (it catalyses 97%-99.9% methyla-
tion reactions during mitosis) while DNMT3A and
DNMT3B conduct from 3% to 5% of methylation in
the newly-synthesized DNA (de novo methylation)
[22,24]. 
The mechanism of DNMTl activity is well known.
In the S phase of cell cycle, this protein reaches its
maximum concentration and creates a complex with
nuclear antigen of proliferating cells (PCNA). PCNA
surrounds the DNA like a ring and moves along mak-
ing it possible for methyltransferase to fulfill a catalyt-
ic function. DNMTl recognizes hemimethylated CpG
dinucleotides in maternal and daughter DNA strand
and moves the methyl group from the S-adenosyl-
methionine (SAM) to the cytidine located in the
unmethylated daughter strand. As a result of this
process, there appear symmetrically methylated sites
corresponding to the template DNA particle (Fig.
1,2)[10,15,23].
DNMT3A and DNMT3B are of particular impor-
tance in the early stages of embryonic development.
They establish the methylation pattern which is trans-
mitted to the differentiating cells and tissues. The role
of de novo methyltransferases in mature cells has not
been fully explained. It is suspected that DNMT3B
maintains pericentric heterochromatin in the state of
methylation. It is because DNMT3A and -3B have a
conservative PWWP domain (binding to DNA)
responsible for the localisation of these proteins with-
in the pericentric heterochromatin  [25-27].
Moreover, DNMT1 and DNMT3B are involved in
the suppression of human rDNA. DNMT3B protein
participates in this process probably via the PWWP
domain and the ATRX-homology domain (cysteine
rich zinc finger DNA binding motif), which takes part
in the protein-protein interactions [25,26].
It has also been found that the alternative splicing
of the DNMT3B primary transcript leads to the forma-
tion of one of the five mRNA izoforms (from
DNMTB1 to DNMTB5). These particles differ in single
exons. DNMT3B1, which is the only one to undergo
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Fig. 2. Inheritance of the DNA
methylation pattern. The mainte-
nance methylase can methylate
only the CG sequence paired with
methylated CG. The CG sequence
not paired with methylated CG
will not be methylated. Hence, the
original pattern can be maintained
after DNA replication [57].
expression in embroynic stem cells, contains a full set
of exons. The remaining DNMT3B do not have from
two to four exons and are active in some cancer cell
lines, e.g. DNMT3B2 in breast cancer, DNMT3B3 in
bladder cancer and DNMT3B4 in hepatocellular carci-
nomas (HCC) [28].
The DNMT3L protein may indirectly participate in
the process of DNA methylation. While it does not
have catalytic activity by iteself, when it accompanies
de novo methyltransferases, it stimulates their activity
and increases their DNA affinity [29].
DNA demethylation
A passive DNA demethylation happens when the
activity of methyltransferases is blocked or their con-
centration is low. Methylation loss usually follows two
rounds of replication, between which there is no
methylation within the previously methylated DNA
sequence. During replication DNMTl may be unable
to methylate newly-synthesized DNA, e.g. due to the
reaction with 5-azacytidine (5-azaC) - an irreversible
inhibitor of methylotransferases, or as a result of cyti-
dine methylation blocking by some proteins binding to
DNA during the S phase of cell cycle [23,30].
The synthesis of DNMTl and DNMT3B enzymes
may be limited already at the transcription stage due to
interactions between antisense oligonucleotides -
small interfering RNA (siRNA) and 3'untranslated
region of genes. The studies perform on CP70 ovarian
cancer cell lines has shown that the transfection of can-
cer cells by adequately designed siRNA molecules
induces DNMT1 and DNMT3B mRNA degradation,
which inhibits the sythesis of protein products of both
genes [31].
The process of demethylation may also have an
active character and involve DNA demethylases. One
of the proteins showing such activity is 5-methylcyto-
sine DNA glycosylase (5-MCDG). It creates a complex
with an RNA molecule (necessary for its activity) and
RNA helicase. A similar activity is characteristic for
MBD4 - a protein binding methylcytosine and repairing
mismatched  base pairs (mismatch repair) [23].
The influence of methylation on gene expression
A role for DNA methylation in the regulation of gene
expression was suggested many years ago. Early
research indicated a correlation between the site-spe-
cific cytidine methylation within or adjacent to genes
and transcriptional repression. It has been proved that
the methylation of CpG islands of promoter region is
often related to the loss of gene expression while there
is a weak relationship between gene expression and the
methylation of CpG dinucleotides located in the gene
coding sequence situated outside the first exon [28].
The inverse relationship between promoter region
methylation and transcription has been observed in
many genes, but not in all of them. In the genes with-
out CpG islands, a strong promoter with several CG
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Fig. 3. Methylation DNA in normal and tumor cells [58].
pairs may be resistant to silencing by methylation
while a weak promoter usually remains sensitive [22].
Due to the fact that the methylation pattern influ-
ences gene expression and is inherited during the
mitotic division without causing changes in DNA
sequence, DNA methylation has been classified as an
epigenetic gene regulation mechanism.  Several ways
of transcriptional suppression by methylation have
been suggested. 
The modification of cytidine (to 5-methylcytidine)
located in the site recognized by specific transcription
factors may block the binding of these factors and
inactivate the gene (Fig. 3). Transcription factors
which are sensitive to methylation include, among oth-
ers: AP-2, cMyc/Myn, CREB, E2F, NFκB. Other tran-
scription factors (e.g. SPl, CTF) bind both to methy-
lated and unmethylated sequences [10,28,32]. The SPl
transcription factor reacts with Alu hypermethylated
sequences, which surround the promoters of some
housekeeping genes. The binding of such a factor
blocks the spreading of methylation to CpG islands
and maintains the gene in an active state [15].
Transcription factors binding sites may be occupied
by proteins stimulating chromatin condensation.
Changes in chromatin structure are caused by proteins
binding methylated cytosine: MeCP-2, MBD1, MBD2,
MBD3, MBD4, which bind to the methylated sites of
CpG regardless of the neighbouring sequences
[10,20,33].
MeCP-2 is not necessary to keep embryonic stem
cells alive, but it is vital for the embryonic development.
The human MeCP-2, gene, which consists of 3 exons, is
situated in Xq28 and the protein it codes contains 489
amino acids. This gene is alternatively polyadenylated in
3' untranslated regions (UTR) producing several tran-
scripts more than 10.1 kb long. Transcript expression is
different in the brain than in other tissues [33].
MeCP-2 contains two domains: MBD (methyl-CpG
binding domain), which binds unmethylated DNA and
TRD (target recognition domain), which ihibits tran-
scription and may bind to unmethylated DNA consti-
tuting nucleosomes or a more compacted form of
chromatin. 85 amino acids (from 78 to 162) situated at
the N-end of MBD recognize single methylated CpG.
104 amino acids of TRD (from 207 to 310) react with
a large comlex of  Sin3 co-repressor, which consists of
at least seven subunits and covers histone deacetylases
HDAC1 and 2, proteins binding histones RbAP48 and
46 and Sin3A, SAP30 and SAP18.  Sin3 complex
shares four proteins (HDAC1, 2 and RbAP48, 76) with
NuRD complex, which is a part of MBD4. RbAP48
reacts directly with histone deacetylase and strength-
ens enzymatic activity, probably by means of binding
deacetylase to the proper site, which causes deacetyla-
tion of the N-end domain of histone H4 and makes
chromatin more compact [33].
The structure of MeCP-2 protein suggests that it
takes part in two main gene regulation mechanisms:
DNA methylation and histone deacetylation. In some
cases, it has been proved, however, that in transcrip-
tion inhibition DNA methylation dominates histone
deacetylation. MeCP-2 participates in the formation of
a more stable, inactive chromatin structure, but it can
also inhibit the transcription of even “naked” DNA,
which means that the formation of chromatin is not
necessary for its activity. The silencing of gene expres-
sion by proteins binding methylated DNA is probably
significant while inheriting X chromosom inactivation
[5,10,20].
Methylation during embryonic development
DNA methylation is tissue-specific and may control
gene expression during embryonic development. The
lack of a functional gene of DNA methyltransferase in
mice causes their death within the first eight days of
pregnancy [10].
Changes in DNA methylation pattern occur during
the normal development and differentiation of mam-
malian cells. In the zygote, immediately after the fer-
tilization, there are dynamic histone modifications and
fluctuations of DNA methylation levels. Using methy-
lation-sensitive restriction enzymes, it was found that
a dramatic reduction in methylation levels (the, so-
called, global demethylation) occurs in the early
embryo. After implantation, this is followed by a wave
of de novo methylation involving most CpG sites. Dur-
ing gastrulation, tissue-specific genes are demethylat-
ed in their tissues of expression, but the majority of the
genome remains methylated. The last wave of de novo
methylation is sex-dependent and takes place during
gametogenesis. A slow decrease in the DNA methyla-
tion level has been observed during postembryonic life
as well as in vitro in ageing cells. [19,34-36].
Aberrations in the methylation pattern in cancer
Changes in the overall methylation level and methyla-
tion pattern of particular genes are characteristic for
different types of cancer cells. Research has shown
that both hypomethylation and hypermethylation of
DNA are connected with cancer. The influence of
DNA methylation on oncogenesis may involve one of
the following mechanisms: 
1. DNA hypomethylation (a global demethylation
inside the genes and a local one in gene promot-
ers)
2. hypermethylation of tumor suppressor genes
(within normally unmethylated  CpG islands)
3. transition of 5-methylcytosine to thymine and
"non-CpG" methylation in tumor cells
4. induction of chromosomal instability.
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DNA hypomethylation 
It has been found that there are differences between
hypomethylation levels in the same type of cancer as
well as between different types of cancer. Hypomethy-
lation, in comparison to normal tissues, has been
observed in numerous  solid tumors and in some
haematological malignances. In colorectal cancer,
there was a 10%-30% average reduction in the overall
methylation and in precancerous forms of adenomas
there was a significant decrease of 5-meC. There is a
clear hypomethylation (over 50%) in chest tumors. As
regards haematological malignances, hypomethylation
is observed in chronic lymphocytic leukaemia (CLL)
whereas in the case of chronic myelogenous leukaemia
(CML), acute myelogenous leukaemia (AML) and in
multiple myeloma, only small changes in total DNA
methylation have been observed. In the case of haema-
tological  and some other malignances, it is difficult to
define correctly normal cells or tissues, which would
serve as a control [20].
Global demethylation occurs at different moments
and its role in the initiation and progress of cancer is
different for its particular types. Global demethylation
appears in the early stages of chest tumors, colorectal
cancer and CLL. In colorectal cancer, hypomethyla-
tion is observed in healthy tissues adjacent to the
tumor, which suggests its role in disease initiation. In
other tumors, e.g. hepatocellular carcinoma, hypo-
methylation increases together with tumor's  histologi-
cal stage and advancement [20].
Total DNA methylation is significantly influenced
by the activation of usually inactive transpozones and
endogenous retroviruses, which are present in the
human genome.  LINE (long interspersed nuclear ele-
ments), which belong to retrotranspozones, show a
high degree of methylation in all types of mammalian
tissues. Moreover, most mammalian genes contain
retrotranspozones situated inside introns. The activa-
tion of a strong promoter connected with these ele-
ments may change completely the transcription level
and modify the expression of genes within which these
elements appear. It is also believed that unmethylated
transpozones cause mutations in the genome and
abnormal chromosomal recombinations in the dis-
persed form of chromatin [20,28].
Gene-specific methylation occurs in numerous
colon, pancreas, chest, stomach, prostate cancers,
lukaemia and others. It happens in the genes regulating
the growth, coding enzymes, genes significant for the
development, tissue-specific genes and oncogenes. In
liver cancer, was observed hypomethylation of C-
MYC, C-FOS, H-RAS, K-RAS protooncogenes. There
is a strong correlation between the state of specific
CpG dinucleotide methylation in the third exon of C-
MYC gene and human hepatocellular tumours [37].
This dinucleotide is also methylated in some chronic
leukaemia and colorectal cancers. In leukaemia, there
is also a decrease in the level of ERB-A1 and BCL-2
gene methylation whereas in lung and colorectal can-
cer we observe a decrease in the amount of K-RAS
protooncogene [20].
DNA hypermethylation 
Hypomehtylation of the genome leads to nonrandom
changes in the localisation of methyl groups. Some
DNA regions show hypermethylation even if the total
concentration of 5-methylcytidine is decreasing [10].
It has been found that there are, so-called, hot spots for
hypermethylation on chromosomes 3p, 11p and 17p in
various human cancers. They include  CpG islands,
which are normally never methylated in vivo, and in
tumor cells they undergo methylation, sometimes even
in the early stage of cancerogenesis [13].
In addition to point mutations or gene deletions,
promoter and first exon hypermethylation constitutes
an additional factor which inactivates suppressor
genes. This process silences over 90 genes in various
types of carcinoma [28,38].
Hypermethylation was first described for the calci-
tonin gene located on the  chromosome 11p, in lung
cancer and lymphoma. Later research revealed the
methylation of this gene also in colorectal cancer and
CML [22]. The retinoblastoma (RB) gene appeared to
be the first classical tumor suppressor gene where
hypermethylation was discovered within 600 bp long
CpG islands situated at the 5' end:  in retinoblastomas
(ca. 10%), gliomas (25%), bladder cancers, hypophy-
seal adenomas, in many small cell lung cancers
(SCLC) and some non-small lung cancers (NSCLC)
(30%)) [10,38,39]. This gene is located on the chro-
mosome, 13q, in  band 14 and consists of 27 exons. It
has also been shown that in vitro methylation of RB
gene promoter region blocks the activation of this pro-
moter and may limit expression to 8% in relation to the
unmethylated conrol [40]. 
One of important cell cycle regulatory proteins is
p16 (INK4A) coded by the gene located at 9p21, which
- using an alternative reading frame - also codes a struc-
turally and functionally different protein - p14 (ARF)
[8,41,42]. P16 binds cyclin-dependent kinases (cdk4
or cdk6) stopping them from creating an active com-
plex with cyclin D, which halts the pRb/p130 pathway
in the early G1 phase of cell cycle. A spontaneous
arrest of p16 expression has been observed in small
colonies of normal human breast epithelial cells grow-
ing in a standard, serum-free medium, which increased
the number of divisions by 40-50 in relation to the nor-
mal division. It is believed that the methylation of p16
CpG islands plays a role in the spontaneous silencing
of this gene, and treating cells with 5-aza-2'-deoxycy-
tidine (methylase inhibitor) causes the renewal of p16
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expression and a normal growth inhibition.  In some
types of human cells the level of p16 tends to accumu-
late, which may cause an increase of this gene's
expression in ageing cells increase by up to forty times
in comparison with freshly passaged cells [42]. Muta-
tions and methylation resulting in p16 silencing are
often observed in human primary tumours: bladder
tumor, nose and throat tumour, melanoma, glioma,
pancreas cancer, leukaemia, colorectal and lung can-
cer [43].
A different study focused on the hypermethylation
profile of 15 types of primary tumours (colon, stom-
ach, pancreas, liver, kidney, lung, head and neck,
breast, ovaries, bladder endometrium, brain,
leukaemia, lymphoma). The analysis covered 3 groups
of genes: tumor suppressor genes (p16, p15, p14, p73,
APC and BRCA1), DNA repair or xenobiotic
metabolising genes (hMLH1, GSTP1, MGMT) and the
genes responsible for metastases and invasiveness
(CDH1, TIMP3, DAPK). Methylation in at least one
gene was found in every type of carcinoma. Methyla-
tion profiles appeared to be both tumour and gene spe-
cific. Some genes, like p16, as well as MGMT and
DAPK were methylated in various carcinoma (colon,
ovarian, lung, head and neck cancer, leukaemia, blad-
der, lymphoma). P14 and APC hypermethylation tend-
ed to spread in gastrointestinal tumours (colon, stom-
ach) and in GSTP1 it was characteristic for steroid-
dependent tumours (breast, liver, prostate) [77]. 
The above results have been confirmed by research
focusing on single types of tumour. MGMT and APC
have been analysed in colorectal cancer, p14 in stom-
ach cancer, DAPK in bladder cancer, and GSTP1 in
liver cancer. Methylation appeared to depend on tumor
type in the following genes: BRCA1 (breast and ovari-
an cancer), hMLH1 (rectal, endometrial and gastric
cancer), p73 and p15 in leukaemia [44].
Subsequent analyses have also proved the influence
of epigenetic inactivation on molecular pathways
engaged in cell immortalisation and tumour transfor-
mation [8]. Promoter hypermethylation was observed
in connection with the silencing of genes involved in
cell cycle (p16 i p15), DNA repair (hMLH1, MGMT i
BRCA1), cell adhesion and metastasis formation
(CDH1, TIMP3, DAPK), related to p53 (p14 i p73) and
to metabolic enzymes (GSTP1) and APC/β-cathenin
(APC) pathway. Aberrations in the methylation pat-
terns of genes belonging to different pathways were
diversified in various tumour types. Considering the
gene-specific methylation profile, it was noticed that
gastrointestinal tumors (colon, stomach) share few of
hypermethylated genes (p16, p14, MGMT, APC,
hMLH1) whereas lung, head and neck cancers have
different patterns of hypermethylated genes: DAPK,
MGMT, p16 and similar in the case of hMLH1 and
p14. Breast and ovarian cancers show a tendency to
methylate BRCA1, GSTP1 and p16. Changes in
haematological malignances differ from those in solid
tumours, which is apparent in the high methylation fre-
quency in the case of p73 and p15, which are not
methylated in tumours of epithelial origin. Epigenetic
lesions were often found already in the early stages of
tumor development. Hypermethylation of p16, p14,
MGMT and APC gene promoters occurred in colorec-
tal adenomas,  p16 in basal cell hyperplasia squamous
metaplasia and in the carcinoma in situ of the lung, and
hMLH1 was epigenetically silenced in endometrial
hyperplasia and in ulcerative colitis, both in the uterus
and in colorectal cancer [44]. 
Other studies concentrated on lung tumors. The
analysis covered adenocarcinoma and squamous cell
carcinoma, the adjacent cancer-free lung parenchyma,
peripheral blood mononuclear cells (PBMC) and sali-
va. The research focused on 11 genes involved in cell
pathways such as: signal transduction (3-OST-2),
apoptosis (DcR1, DcR2, DAPK), adhesion (APC, 
E-CAD, H-CAD), cell cycle (p16, RASSF1A), cytokine
singalling (SOCS1, SOCS3). Methylation aberrations
in at least one gene were found in 98% of primary
tumors. Methylation frequency ranged from 90% for
3-OST-2 to 40% for DcR2. In the adjacent non-cancer
tissues methylation frequency was 58% for APC and
2,5% for DAPK. No methylation was observed in
PBMC or it was statistically insignificant. The analy-
ses of saliva samples (patients with and without
tumours) showed that 4 out of 11 genes may be used as
potential biomarkers in cancer. Methylation of genes
3-OST-2, RASSF1A, p16 and APC was 62% in the
examined samples and zero in control. Taking into
account the whole examined material, it was stated
that methylation in 9 genes may be a useful biomarker
in non-small cell lung cancer (3-OST-2, RASSF1A,
p16, DcR1, DcR2, SOCS1, APC, DAPK, H-CAD).
Each of the genes could be useful for the differentia-
tion of lung cancer from the adjacent non-cancer tis-
sues, tumors from PBMC and adenocarcinoma from
squamous cell carcinoma.  The authors were the first to
propose the usage of five of these genes as lung cancer
markers  (3-OST-2, DcR1, DcR2, SOCS1 i SOCS2)
[45].
"Non-CpG" methylation and  5-methylcytosine -
thymine transition 
In mouse embryonic stem cells there occurs methyla-
tion which is unconnected with CpG sequences (non-
CpG methylation) [46]. It has also been detected in
promoter-enhancer sequences in an adenoviral vector
containing the CMV-PE-hFGF-4 gene sequence. The
mechanism of different methylation may result from
the DNMT3 activity [41]. DNMT3A and -3B are
responsible for de novo methylation, which, apart from
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CpG, can occur in CpA, CpC and CpT nucleotides sit-
uated in the DNA of embryonic stem cells and episo-
mal DNA [46].
Minimum CpG methylation has also been discov-
ered during the inactivation of virus sequences in cell
lines and in animals.  At least four types of viruses
involved in human lung cancerogenesis can be inacti-
vated in this way: EBV, HPV, HIV, SV40 [47-50]. This
type of cytosine methylation has not been found in
human tumours for many years. 
In human cells, deamination of methylcytosine to
thymine in CpG sequences often leads to mutagenesis.
Several such sequences have been described as muta-
tion hot spots (in lung cancer - codons 157, 248 and 273
of gene p53) [51,52]. It has been found that in non-small
cell lung cancer, in gene p53 there is a significant per-
centage of GC to AT transitions in "non-CpG" sites,
which, according to the expectations, should not be
methylated (44.09% of non-CpG sites) [53]. "Non-
CpG" methylation occurred in three regions of exon 5,
which contain CpA (codons 156-159, codons 175-179,
and the sequence at the 3'end of the gene) [53].
It is now suggested that DNMT3 activation can
cause "non-CpG" methylation in the human gene p53.
In the lung, this type of methylation occurs also in the
tissues adjacent to the tumor, which indicates that
"non-CpG" methylation may appear in the early stage
of canceration and serve as a useful tool for early can-
cer detection [53].
Methylation and chromosomal instability 
A methylation pattern defect, in addition to changing
the level of gene expression, may facilitate the gain
and loss of some chromosomes. These processes lead
to the genomic instability preceding the development
and progression of cancer. 
Microsatellite instability leading to changes in the
number of DNA short tandem repeats has been found
in 35% of SCLC and in 22% of NSCLC [54].
The loss of heterozygosity (LOH) is a frequent
occurrence in lung cancer. In SCLC we observe the
loss of 3p, 4p, 4q, 5q, 8p, 10q, 13q, 17p whereas in
NSCLC we often deal with the loss of 3p, 6q, 8p, 9p,
9q, 13q, 17p, 18q, 19p, 21q, 22q [13].
LOH tests on chromosome 11 carried out on mouse
cell lines have shown that the occurrence of this phe-
nomenon is significantly higher in hypomethylated
cells (77%) than in methylated cells (45%). LOH often
occurred near the centromere (45% of analysed cases).
It is suggested that the increased loss of heterozygoty
in hypomethylated cells might have been caused by the
influence of hypomethylation on the stability of cen-
tromere and pericentric chromatin [55].
There is often a clear cooperation between epige-
netic and genetic phenomena during the generation of
oncogenic phenotype. The silencing of MLH1, which
is a gene coding the protein participating in the repair
of mismatched base pairs, is connected with hyperme-
thylation and leads to the creation of MIN+ phenotype
in lung, endometrial and gastric cancer (70%-80%),
and the epigenetic inactivation of the gene coding glu-
tation S-transferase 1 (GSTP1) in prostate, breast and
other cancers predisposes DNA to being damaged by
active forms of oxygen, which may result in adenine
mutations occurring during cancer progression [6].
Epigenetic lesions in tumor cells do not always
occur before genetic changes. The relation between
these aberrations may also be inverse. Genetic
changes in the genes coding transcription factors and
transcription co-activators may modify chromatin in
such a way that, as a result, the normal cell methyla-
tion pattern is broken and there is an epigenetic gene
silencing [6].
Summary
The relationship between the occurrence of  hyperme-
thylation in tumor suppressor gene promoter
sequences and its role in cancerogenesis started to gen-
erate interest in the mid-eighties of the last century.
Further research showed a high degree of total DNA
demethylation in tumour cells.  The knowledge about
the course and role of DNA methylation has enabled
the development of efficient and fast methods of
detecting methylated and unmethylated sequences.
Current research bases on the PCR technique and
analyses methylation patterns both in tumor suppres-
sor genes and oncogenes as well as in extragenic
DNA.  At the beginning of 2007, Shivapurkar et al.,
using Real-Time PCR technique, a proposed five
genes as new markers useful for an early detection of
lung cancer [45]. In the future, the knowledge about
epigenetic changes occurring in the human genome
during cancerogenesis may facilitate an early diagno-
sis and enable the introduction of new, more efficient
methods of cancer treatment. 
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